Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Melanoma 28Neoplasms 15Carcinoma, Non-Small-Cell Lung 7Multiple Myeloma 6Hematologic Neoplasms 6Neoplasm Metastasis 4Lymphoma 4Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Glioma 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Adenocarcinoma, Follicular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2efatutazone 2Sorafenib 2Radiotherapy, Intensity-Modulated 2trametinib 1tislelizumab 1surufatinib 1spartalizumab 1sapanisertib 1lenvatinib 1fosbretabulin 1dabrafenib 1crolibulin 1combretastatin 1cabozantinib 1atezolizumab 1abemaciclib 1Taxes 1Imatinib Mesylate 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1Carboplatin 1CUDC-907 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × trametinib × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡